Table 5 Survival analysis of clinico-pathological variables and MYC amplification
From: MYC amplification in subtypes of breast cancers in African American women
95% CI | |||||
|---|---|---|---|---|---|
Mean Months | Std. Error | Lower Bound | Upper Bound | p-value | |
Stage | |||||
1 | 119.59 | 9.62 | 100.73 | 138.45 | |
2 | 92.03 | 7.75 | 76.85 | 107.21 | |
3 | 98.25 | 15.12 | 68.61 | 127.89 | |
4 | 18.25 | 6.02 | 6.45 | 30.05 | p < 0.001 |
Size (T) | |||||
T1 | 89.35 | 4.53 | 80.47 | 98.23 | |
T2 | 100.60 | 9.98 | 81.04 | 120.17 | |
T3 | 82.50 | 16.74 | 49.69 | 115.32 | p = 0.06 |
Distant Metastases | |||||
No Metastatic Disease (0) | 114.88 | 7.06 | 101.05 | 128.71 | |
Metastatic Disease (1) | 38.78 | 13.97 | 11.40 | 66.16 | p < 0.001 |
Lymph Nodes | |||||
Lymph Node Negative (0) | 124.65 | 8.29 | 108.40 | 140.90 | |
Lymph Node Positive (1) | 86.88 | 10.33 | 66.64 | 107.11 | p = 0.039 |
Breast Cancer Molecular Subtype | |||||
Luminal A | 67.71 | 7.99 | 52.05 | 83.36 | |
Luminal B | 94.00 | 4.82 | 84.56 | 103.44 | |
HER 2+ | 71.00 | 13.73 | 44.09 | 97.91 | |
Triple Negative Breast Cancer | 100.07 | 11.99 | 76.57 | 123.57 | p = 0.201 |
C-MYC Amplification | |||||
< 2 | 93.96 | 8.96 | 76.41 | 111.52 | |
> 2 | 117.03 | 9.98 | 97.47 | 136.59 | p = 0.265 |